Enable Injections

Enable Injections is a healthcare innovation company headquartered in Cincinnati, Ohio, specializing in the development and manufacturing of wearable drug delivery platforms. The company's flagship product is enFuse, a hands-free subcutaneous injection device designed to deliver large medication volumes without intravenous administration. enFuse represents a paradigm shift in patient treatment experience, offering painless, convenient at-home delivery with integrated smart technology capabilities. The company manufactures enFuse in three configurations: wearable injectors, transfer systems for pharmaceutical partners, and smart-enabled versions with digital companion solutions. Enable Injections' commercial product portfolio includes the EMPAVELI Injector, which has received regulatory approval in multiple markets including Saudi Arabia. The company operates manufacturing facilities and maintains partnerships with major pharmaceutical companies including Roche, Sanofi, Apellis, CSL, Incyte, SOBI, Serina, and Viridian Therapeutics for clinical trials and joint commercial launches. Manufacturing capabilities are located in Springdale, Ohio, with business administration and innovation centers in West Chester, Ohio. The platform has received industry recognition from publications such as Fierce Pharma and PM360 for innovative technology and patient-centric design. Enable Injections has secured significant capital investment, including a $30 million funding round from Sanofi announced in January 2026 to accelerate manufacturing capabilities. The company focuses on improving patient quality of life through simplified medication delivery, particularly for chronic disease management requiring frequent or large-volume injections.